Aktuella utlysningar, vecka 43, 2021
Grants Office tipsar om aktuella utlysningar.
Svenska och nordiska utlysningar
Eurolife announces the 7th call for Eurolife Postdoc Mobility and Knowledge Exchange grants 2022
Du som junior forskare vid KI är välkommen att söka medel från Eurolife för ett korttidsutbyte vid ett annat lärosäte inom nätverket.
För detta initiativ, tidigare utlyst som Eurolife Short-term Research Exchanges, anslås 9 bidrag till forskare från lärosätena inom Eurolife med målet att underlätta ytterligare forskningssamarbete.
Bidraget på 1500 EUR är för att täcka rese- och boendekostnader under en utbytesperiod som måste omfatta minst 2 veckor under perioden 1 mars - 31 december 2022.
Closing date: 30 November 2021
Postdoctoral scholarship programme at Stanford University – Knut and Alice Wallenberg Foundation
This enables young scientists to study and perform research at Stanford University in the US, and upon return, receive further support to continue that research in Sweden. The fellowship is tenable for up to two years and comprises a stipend of approximately USD 65,000 per year and a package of health insurance, travel of up to USD 5,000 per year and a family allowance grant of up to USD 15,000 per year.
Closing date: 15 November 2021
Nordic Collaboration Activities – Nordic Trial Alliance (NTA)
Nordic Trial Alliance (NTA) is a NordForsk project to facilitate clinical research co-operation in the Nordic Region and focus on multi-centre clinical trials. Several major health challenges have created an urgent need to push clinical research forward. NTA hereby invites proposals for activities that promote Nordic co-operation on clinical research. More specifically, the purpose of this call is to support activities that aim to build a Nordic platform for participation in upcoming activities at European level, e.g. within Horizon Europe and EU4Health. Activities should strengthen Nordic collaboration and knowledge transfer and deliver concrete outcomes that enhance Nordic clinical research co-operation.
Closing date: 19 November 2021
Extra investment in prevention research – Swedish Heart-Lung Foundation
The Swedish Heart-Lung Foundation, with support from the Norhead Foundation, invites applications for its extra investment in prevention research call. This supports lifestyle-related intervention as part of prevention and treatment research in the cardiovascular field. The grant covers both primary and secondary prevention and the focus should primarily be on diet and physical activity but should also include lifestyle-oriented measures as part of the treatment of cardiovascular disease. Projects that have a broad perspective and highlight the importance of lifestyle issues in society are welcomed.
Research networks consisting of at least two research groups are encouraged to apply. The main applicant can only be awarded the grant once. There are two grant types available: Norhead Foundation, worth up to SEK 2 million per year for up to three years and Heart-Lung Foundation, worth up to SEK 1m per year for up to three years.
Closing date: 23 November 2021
EU-programme Stockholm, extra call – Swedish Agency for Economic and Regional Growth
These support start-up projects based on already completed feasibility studies or to develop an already ongoing EU-project.
Closing date: 30 November 2021
Research Infrastructure Fellows, RIF-2 – Swedish Foundation for Strategic Research (SSF)
To contribute to an increased and more efficient utilization of research infrastructures and at the same time create career paths for key people who work with the development, construction and operation of research infrastructure at Swedish universities, the Foundation for Strategic Research, SSF, is investing 105 million SEK in the RIF-2 call. The call is aimed at people who have chosen a career path other than the classical academic one and who are of crucial importance to the research community. They can be, for example, research engineers, instrument managers, machine or lab managers, that is people who all actively develop the research infrastructure. According to SSF’s statutes, the foundation must support research in science, technology and medicine and the call is therefore aimed at infrastructure in these areas.
Seven persons are appointed, each receiving SEK 15 million over a five-year period. The grant will cover salary, research infrastructure tools and running costs.
Closing date: 15 February 2022
Fellowship project award – Bayer
Bayer, under its haemophilia awards programme, invites letters of intent for its fellowship project award. This supports the development of clinical and research expertise in the field of haemophilia for applicants who have completed medical training and have an interest in pursuing a career as a haemophilia clinician.
Applicants should be affiliated with either a medical university, hospital, treatment centre, blood centre or laboratory and should have earned their medical degree within the previous eight years. Awards are worth up to USD 80,000 each for one year.
Closing date (Letter of intent): 30th November 2021
Patient engagement award - Bayer
Bayer, under its haemophilia awards programme, invites letters of intent for its patient engagement award. This supports efforts in the field of patient engagement, education and advocacy within haemophilia, while recognising the essential role of nurses, allied healthcare professionals and caregivers in the care of patients with haemophilia.
Awards are worth up to USD 25,000 over one year.
Closing date (Letter of intent): 30th November 2021
Imagine for Margo – Children without Cancer, KickCancer, the Foundation for Children with Cancer (FKK) and the National Federation of Associations of Parents of Children and Adolescents with Cancer or Leukaemia (FIAGOP) invite applications for their fight kids cancer programme. This aims to catalyse and support pan-European innovative and relevant research initiatives in paediatric cancer.
Projects may aim to develop new therapies that improve the outcome for all children and adolescents with cancer. There are two categories of projects: early phase clinical trials conducted in at least two countries, and translation research projects to identify novel mechanisms of action and targets that may result in innovative new therapies or better models of disease. Pre-clinical projects including high-risk/high return proposals, or projects that leverage paediatric tumour models, will be considered. Multi-disciplinary or multi-institution collaborations are strongly encouraged.
For this call, funding limits are: 1) early phase clinical trials max EUR 1.5 million per project and 2) translational research project max EUR 500 000 per project.
Closing date (Expression of interest): 30th November 2021
Osteology researcher grants - Osteology Foundation
The Osteology Foundation invites applications for its osteology research grants. These support research on oral tissue regeneration.
Topics may include: Clinical aspects of hard and soft tissue biology; Novel bone and soft tissue substitute materials; Local factors affecting oral tissue regeneration; Systemic diseases with an impact on oral tissue regeneration; Pharmacological aspects of oral tissue regeneration; Inflammatory conditions, such as periodontitis and peri-implantitis.
Applications are open to advanced researchers in the field of oral tissue regeneration and young researchers currently undergoing postgraduate education or within three years thereafter. Grants for advanced researchers are worth up to CHF 100,000 each. Grants for young researchers are worth up to CHF 30,000 each.
Closing date 1 December 2021
Federal Funding agencies
Drug Discovery For Nervous System Disorders (R01, R21 Clinical Trial Not Allowed), NIH
This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders.
This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents
The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-19-147)
Closing date: Standard dates apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-19-146 (R21), PAR-19-147 (R21)
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01, R21 Clinical Trial Not Allowed), NIH
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
Closing date: Standard dates apply. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-20-276 (R01), PAR-20-277 (R21)
Investigator Initiated Research in Computational Genomics and Data Science (R01, R21 Clinical Trial Not Allowed), NIH
The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.
Funding Opportunity Announcement (FOA): PAR-21-254 (R01), PAR-21-255 (R21)
Research grants - Cystic Fibrosis Foundation, US
The Cystic Fibrosis Foundation invites applications for its research grants. These encourage the development of new information that contributes to the understanding of the basic aetiology and pathogenesis of cystic fibrosis. Studies must focus on basic science research.
Applications must be independent investigators.
Awards are worth up to USD 125,000 per year for up to two years, with the possibility of renewal.
Closing date: December 7, 2021 by 5 p.m. ET.
Institutional movement disorder fellowship – research centres of excellence - Parkinson’s Foundation, US
The Parkinson’s Foundation, under its institutional movement disorder fellowship programme, invites applications for its research centres of excellence funding opportunity. This supports innovative team science at institutions working on a thematic area of Parkinson’s disease. Proposals must tackle critical issues or problems that are impeding progress in the field of Parkinson’s disease research. Preference will be given to applications which demonstrate cross-departmental or cross-institutional collaboration.
This award program is open to an interdisciplinary team of scientists working in the field of Parkinson’s disease. Each team should have at least three PIs at the faculty-level and may also include postdoctoral fellows, graduate students and research technicians. The team may all reside in the same geographical area and work at the same institution or collaborate through a virtual center with scientists spread across regions and institutions.
Awards are $500,000 a year for 4 years, for a total award of $2,000,000. Of this, USD 50,000 per year must be reserved for pilot work and new collaborations. Up to 10% ($200,000) of the total award may be used towards indirect costs.
Closing date: Application Due: February 4, 2022; Award Notification: April 15, 2022; Award Begins: July 1, 2023.